Tonix Pharmaceuticals is currently enrolling participants in a Phase 3 trial for posttraumatic stress disorder (PTSD). For more information, please visit www.recoverystudy.com or www.clinicaltrials.gov (NCT03841773).

News / Press Releases

: Press Releases

Press Releases

Tonix Pharmaceuticals Announces that Breakthrough Therapy Designation Remains in Effect for Tonmya® for the Treatment of Posttraumatic Stress Disorder

April 22, 2019 • 7:00 AM EDT

Tonix Pharmaceuticals Plans to Expand TNX-102 SL Phase 3 Program Beyond PTSD to Include Fibromyalgia

April 4, 2019 • 7:30 AM EDT

Tonix Pharmaceuticals to Present at Upcoming Investor Conferences

March 25, 2019 • 8:00 AM EDT

Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Operational Highlights

March 18, 2019 • 8:00 AM EDT

Tonix Pharmaceuticals to Participate at Upcoming Investor Conferences

March 12, 2019 • 7:30 AM EDT

Tonix Pharmaceuticals Enrolls First Participant in the “RECOVERY” Study -- a New Phase 3 Trial of Tonmya® for the Treatment of Posttraumatic Stress Disorder

March 11, 2019 • 7:00 AM EDT

Tonix Pharmaceuticals Announces New European Use Patent for TNX-601

March 7, 2019 • 4:15 PM EST

Tonix Pharmaceuticals Provides Update on Tonmya® for the Treatment of Posttraumatic Stress Disorder

March 1, 2019 • 5:41 PM EST

Tonix Pharmaceuticals Announces Share Repurchase Program

March 1, 2019 • 4:00 PM EST

Tonix Pharmaceuticals Announces New Board Member, James Treco

February 19, 2019 • 4:30 PM EST

« Previous
1
2
3
4
5
6
7
8
9
10
...28
Next »

Show All

News / Press Releases : Press Releases